Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Gross

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Blood|July 15, 2017
Soluble P-selectin is the smoke, not the firePeter L Gross
Blood|September 30, 2021
A long-half-life, high-affinity P-selectin inhibitorPeter L Gross
Blood|March 19, 2011
Salivary microvesicles clot bloodPeter L Gross
JACC. Cardiooncology|May 5, 2023
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism PatientsStephanie Carlin, Peter L Gross
British Journal of Anaesthesia|July 12, 2023
What can ex vivo experiments contribute to clinical haemostasis management?Keyvan Karkouti, Peter L Gross
Frontiers in Medicine|September 13, 2017
Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight HeparinsAlannah Smrke, Peter L Gross
Thrombosis Research|February 23, 2010
Tissue factor microparticles and haemophiliaPeter L Gross, Nima Vaezzadeh
Arteriosclerosis, Thrombosis, and Vascular Biology|February 26, 2008
New anticoagulants for treatment of venous thromboembolismPeter L Gross, Jeffrey I Weitz
Frontiers in Medicine|February 15, 2021
Thromboembolism in Older AdultsPeter L Gross, Noel C Chan
Hematology. American Society of Hematology. Education Program|December 13, 2012
New oral anticoagulants: which one should my patient use?Jeffrey I Weitz, Peter L Gross
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Blood|July 15, 2017
Soluble P-selectin is the smoke, not the firePeter L Gross
Blood|September 30, 2021
A long-half-life, high-affinity P-selectin inhibitorPeter L Gross
Blood|March 19, 2011
Salivary microvesicles clot bloodPeter L Gross
JACC. Cardiooncology|May 5, 2023
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism PatientsStephanie Carlin, Peter L Gross
British Journal of Anaesthesia|July 12, 2023
What can ex vivo experiments contribute to clinical haemostasis management?Keyvan Karkouti, Peter L Gross
Frontiers in Medicine|September 13, 2017
Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight HeparinsAlannah Smrke, Peter L Gross
Thrombosis Research|February 23, 2010
Tissue factor microparticles and haemophiliaPeter L Gross, Nima Vaezzadeh
Arteriosclerosis, Thrombosis, and Vascular Biology|February 26, 2008
New anticoagulants for treatment of venous thromboembolismPeter L Gross, Jeffrey I Weitz
Frontiers in Medicine|February 15, 2021
Thromboembolism in Older AdultsPeter L Gross, Noel C Chan
Hematology. American Society of Hematology. Education Program|December 13, 2012
New oral anticoagulants: which one should my patient use?Jeffrey I Weitz, Peter L Gross
Pageof 8